← brief for 2026-09-28 · Slowing decline

EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted Therapy.

Guideline No results yet Not peer reviewed

Key takeaways

This is a set of medical guidelines for treating a type of fatty liver disease. It gives doctors advice on when to use two specific drugs. This is a recommendation, not a new study with results.

Who did this work

European Association for the Study of the Liver (EASL). Electronic address: [email protected] · European Association for the Study of Diabetes (EASD) · European Association for the Study of Obesity (EASO)

Source

Guideline · PubMed, the drug frontier · 2026 Dec 1
https://pubmed.ncbi.nlm.nih.gov/42805503/